MedTrace Logo

Breath Samples Collection Clinical Trial, for Development of the TERA BioStation T101, Intended for CoV-19 Exhalation Products Detection.

NCT05162495 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2022-01-11

No results posted yet for this study

Summary

The Sponsor has developed a rapid screening tool intended to determine if the subject tested has COVID-19.

Conditions

Interventions

DEVICE

BioStation T101 and TeraTube

Rapid detection of the novel SARS-CoV-2 (COVID-19) virus in breath samples.

Sponsors & Collaborators

  • Tera Group

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2022-06-01
Completion
2022-08-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05162495 on ClinicalTrials.gov